GSK's Phase 3 RUBY Trial Of Jemperli (Dostarlimab) Plus Chemotherapy Meets Endpoint Of Overall Survival In Patients With Primary Advanced Or Recurrent Endometrial Cancer
Portfolio Pulse from Benzinga Newsdesk
GSK's Phase 3 RUBY trial of Jemperli (Dostarlimab) plus chemotherapy has met its endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer.
October 30, 2023 | 8:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
GSK's Jemperli (Dostarlimab) plus chemotherapy has shown positive results in Phase 3 RUBY trial for endometrial cancer patients.
The positive results from the Phase 3 RUBY trial of Jemperli (Dostarlimab) plus chemotherapy could potentially boost GSK's oncology portfolio. This could lead to increased revenues from the drug, which would be positive for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100